AFFIRM-AHF: Ferric Carboxymaltose in Iron-Deficient Patients Discharged After Acute Heart Failure

November 13-17, 2020; Virtual Conference
In patients with iron deficiency, FCM reduced risk of HFH with no apparent effect on risk of CV death.
Format: Microsoft PowerPoint (.ppt)
File Size: 244 KB
Released: November 18, 2020

Acknowledgements

Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Merck

Related Content

High-dose trivalent influenza vaccine comparable to standard-dose quadrivalent vaccine in deaths or cardiopulmonary hospitalizations in high-risk CV disease; AHA results reported by CCO

Released: November 20, 2020

Vericiguat VICTORIA subgroup analysis from AHA, as reported by CCO

Released: November 18, 2020

Omecamtiv mecarbil reduced time to first heart failure event or cardiovascular death in patients with heart failure with reduced ejection fraction: GALACTIC-HF data from AHA 2020 as reported by CCO

Released: November 16, 2020

CCO’s Expert insights from ACC.20/WCC: Akshay S. Desai, MD, MPH discusses recent findings from practice-changing heart failure studies

Akshay Suvas Desai, MD, MPH Released: April 17, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue